Michael Makris on Rising Malignancy Concerns After Hemophilia Gene Therapy: Key Challenges Highlighted in NEJM
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, posted on LinkedIn:
”There is an interesting discussion about the issue of malignancy in persons with haemophilia who have had gene therapy in the New England Journal this week.
The number of malignancies is increasing as more patients undergo gene therapy.
The key issues are:
a) Need for a standardised set of investigations
b) Need for advice on what tissue sample to collect and how to store them, to allow for the more specialised investigations
c) The interpretation of the results
d) Payment for these very expensive investigations. Manufacturers have funded these so far because most of the cases were seen in the clinical trials, but will they continue to fund it long term? ”
Stay updated with Hemostasis Today.
-
Mar 19, 2026, 18:29Rameez Ashraff: Have You Noticed Neutrophil Inclusions in a Thrombocytopenia Smear?
-
Mar 19, 2026, 18:07Leonardo Roever: A Consensus Framework for Biomarker Research and Clinical Translation in Stroke
-
Mar 19, 2026, 17:49Matteo Foschi: Breaktrough Stroke on Oral Anticoaugulants for Atrial Fibrillation
-
Mar 19, 2026, 17:30UK Haemophilia Society Continues to Empower Individuals and Families Through Advocacy, Education, and Community Support – WFH
-
Mar 19, 2026, 17:20Dimitrios Nikas: Stroke During TAVI Procedures Still Remains Noticeable High
-
Mar 19, 2026, 17:14Akinchan Bhardwaj: Differences in Bleeding Outcomes Among DOACs
-
Mar 19, 2026, 17:03How Personal Experiences Can Support Self‑Advocacy and Help Improve Healthcare Outcomes – Hemophilia Alliance
-
Mar 19, 2026, 16:54X. Long Zheng: Unpacking the Real-World Challenges of ADAMTS13 on ISTH Pulse Podcast
-
Mar 19, 2026, 16:50Zain Khalpey: Predictive Imaging and AI in Aortic Dissection Risk Assessment